Glenmark working on proprietary product rollout

Glenmark Pharmaceuticals plans to to launch a number of proprietary products over the next decade as part of its objective to become a specialty-driven firm.
The company's long-term focus is to "launch innovative and specialty products across markets" with significant share of revenues coming from specialty and innovation segment", Glenmark Pharmaceuticals said in its latest investor presentation.
It will also focus on organic growth and leveraging internal capabilities across markets, it added.
In the medium term, the emphasis is on "continuing to grow base generics business" with the US, India and Europe to be main growth drivers, Glenmark said.
The company plans to build a global manufacturing footprint, increase presence in complex generics, launching of specialty business in the US and Western Europe, it added.

Also part of the medium-term focus is a new molecular entities (NME) pipeline at an advanced stage of development.

The company's manufacturing base is primarily in India, with the US and India contributing around 60 per cent of sales.
"The company's NME pipeline in early to mid stages of development," Glenmark said. While it is a generic formulation player in US and Western Europe, it is into branded formulation in other markets.
The company's business is primarily structured into three segments -- branded and generics formulations, active pharmaceutical ingredients, and new molecular entities and specialty, Glenmark Pharmaceuticals said.